Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Katherine Robertson

Nurse Practitioner, Gerontology Texarkana, AR Nurse Practitioner

NPI 1407203425 CMS profile 11127519

1307 Trinity Blvd, Texarkana, AR 71854

Open in the dashboard

General payments

$3,844

203 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Katherine Robertson of Texarkana, AR is reported in the CMS Open Payments database as having received $3,844 across 203 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner, Gerontology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $588 20
2024 General $805 40
2023 General $996 56
2022 General $807 46
2021 General $648 41

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Katherine Robertson
  • Nurse Practitioner, Gerontology median
  • Middle half of Nurse Practitioner, Gerontology
  • National median

In program year 2025, general payments to Katherine Robertson were reported at $588. Among 4,139 Nurse Practitioner, Gerontology profiles paid that year, the median was $179 and the middle half received between $55 and $547.

Show as a table
Year Katherine Robertson Nurse Practitioner, Gerontology median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $648 $133 $44–$396 $132
2022 $807 $142 $48–$452 $149
2023 $996 $158 $53–$482 $160
2024 $805 $171 $55–$533 $164
2025 $588 $179 $55–$547 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $528 33 payments
  2. AstraZeneca Pharmaceuticals LP $437 23 payments
  3. Pfizer Inc. $323 20 payments
  4. Merck Sharp & Dohme Corporation $303 19 payments
  5. GlaxoSmithKline, LLC. $247 15 payments
  6. Amgen Inc. $231 12 payments
  7. Abbott Laboratories $231 9 payments
  8. Lilly USA, LLC $207 13 payments
  9. AbbVie, Inc. $180 4 payments
  10. Sanofi-Aventis U.S. LLC $170 12 payments
  11. Other $986 43 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $3,833 202 payments
  2. Education $11 1 payment
Products named General payments · program years 2021–2025
  1. Ozempic $455 28 payments
  2. RYBELSUS $414 30 payments
  3. VERQUVO $303 19 payments
  4. BELSOMRA $293 18 payments
  5. FARXIGA $265 11 payments
  6. BREZTRI $249 12 payments
  7. TRELEGY ELLIPTA $230 14 payments
  8. ELIQUIS $200 12 payments
  9. YUPELRI $166 7 payments
  10. MOUNJARO $163 10 payments
  11. Other $3,232 164 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

6,143

Median for Nurse Practitioner: 389

Drug cost

$624,042

Median for Nurse Practitioner: $21,885

Branded share of claims

18.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 125 $134,903
Ozempic Semaglutide Brand 84 $107,326
Rybelsus Semaglutide Brand 47 $72,431
Farxiga Dapagliflozin Propanediol Brand 51 $48,048
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 37 $42,209
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 48 $32,947
Soliqua 100-33 Insulin Glargine/Lixisenatide Brand 39 $27,777
Mounjaro Tirzepatide Brand 21 $23,519
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 34 $23,412
Breo Ellipta Fluticasone/Vilanterol Brand 27 $15,629

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 51 billing codes

Paid by Medicare

$166,960

Of which drugs: $72,798

Medicare patients

318

Average age 77

Services billed

7,851

227 women, 91 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 47%
Ischemic heart disease 32%
Chronic kidney disease 31%
Osteoporosis 26%
Diabetes 25%
COPD 25%
Atrial fibrillation 24%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 30 2,940 $59,775
Pcv20 vaccine im 90677 Office 19 19 $5,522
Vaccine for influenza for injection into muscle 90662 Office 66 66 $5,390
Injection, methylprednisolone acetate, 1 mg J1010 Office 27 2,120 $213

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 24 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
FARXIGA
  • AstraZeneca Pharmaceuticals LP $122
$122 51 —
YUPELRI
  • Mylan Specialty L.P. $102
$102 — —
BREZTRI
  • AstraZeneca Pharmaceuticals LP $66
$66 48 —
TRELEGY ELLIPTA
  • GlaxoSmithKline, LLC. $55
$55 34 —
AIRSUPRA
  • AstraZeneca Pharmaceuticals LP $51
$51 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 24 in the dashboard with a free account

Records

203 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Gerontology in Arkansas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record